Charles River Laboratories International (CRL) EBIT: 2009-2025
Historic EBIT for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $133.8 million.
- Charles River Laboratories International's EBIT rose 13.96% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.9 million, marking a year-over-year decrease of 73.31%. This contributed to the annual value of $227.3 million for FY2024, which is 63.17% down from last year.
- Per Charles River Laboratories International's latest filing, its EBIT stood at $133.8 million for Q3 2025, which was up 33.62% from $100.1 million recorded in Q2 2025.
- Charles River Laboratories International's EBIT's 5-year high stood at $187.4 million during Q2 2022, with a 5-year trough of -$167.7 million in Q4 2024.
- In the last 3 years, Charles River Laboratories International's EBIT had a median value of $132.9 million in 2023 and averaged $104.8 million.
- Per our database at Business Quant, Charles River Laboratories International's EBIT spiked by 79.18% in 2021 and then crashed by 226.15% in 2024.
- Charles River Laboratories International's EBIT (Quarterly) stood at $172.8 million in 2021, then dropped by 5.21% to $163.8 million in 2022, then dropped by 18.86% to $132.9 million in 2023, then crashed by 226.15% to -$167.7 million in 2024, then grew by 13.96% to $133.8 million in 2025.
- Its last three reported values are $133.8 million in Q3 2025, $100.1 million for Q2 2025, and $74.7 million during Q1 2025.